Date:10/26/2011

ffected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About SAFC®: SAFC is the custom manufacturing and services business unit of Sigma-Aldrich Corporation. We are recognized as a top 10 global fine chemical supplier and trusted manufacturer of specialty chemicals and biologics for the life science and high technology industries. Utilizing global "Centers of Excellence" and dedicated manufacturing facilities, SAFC can often resolve development and manufacturing challenges and accelerate the production of custom materials. Our rich portfolio includes high-purity inorganic materials for high technology applications, cell culture products, services for biopharmaceutical manufacturing and biochemical production, and complex, multi-step organic synthesis of APIs and key intermediates. For more information about SAFC, visit www.safcglobal.com<
'/>"/>

SOURCE Sigma-Aldrich Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. USRBC President Ed Verona Lauds GE Announcement on Energy and Healthcare Joint Ventures in Russia
2. Hamilton Company Wins Switzerlands 2010 Tell Award for Manufacturing Investment in Grisons, Greater Zurich Area
3. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
4. VaxyGen Manufacturing Services LLC Announces Exclusive License and Collaborative Agreement with Georgia State University Research Foundation to Commercialize Novel Biological Process Development Patent, Expertise & Know-How
5. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
6. FDA Awards NIPTE Potential $35 Million in Grants to Reform Drug Manufacturing Process
7. Pharmaceutical Contract Manufacturing: World Market Outlook 2011-2021
8. Director of Commerce, Rogers Weed, Presided Over Ribbon Cutting Ceremony Celebrating Opening of Expanded Manufacturing Facility at CMC Biologics
9. Global Markets for Contract Pharmaceutical Manufacturing, Research And Packaging: Focus on Emerging Markets
10. Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets
11. Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging: Focus on North America